● Recruiting

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Condition: Biliary Tract Cancer · Sponsor: Eisai Co., Ltd.

PhaseN/A

Planned participants60

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

The primary purpose of this study is to investigate the safety of Tasfygo.

This description comes directly from the study's public registry record.

Talk to the study team

Eisai Inquiry Service · eisai-chiken_hotline@hhc.eisai.co.jp

Always discuss trial participation with your own doctor first.

Locations (1)

#Eisai Trial Site 1

Tokyo, Japan

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06793709